Embattled Canadian pharmaceutical company Valeant named as its new chief executive and chairman on Monday Joseph Papa, who has left his post leading Perrigo, a maker of over-the-counter medical products.
Papa, 60, will succeed outgoing Valeant CEO Michael Pearson as the company faces criticism over its accounting and drug-pricing policies.
Last month, Valeant Pharmaceuticals International announced Pearson would step down once a successor was identified.
"The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time," said Valeant chairman Robert Ingram in a statement.
Ingram praised Papa's leadership skills, deep experience in the global pharma business and said he was known for "fostering an ethical culture."
Perrigo announced separately that it had promoted president John Hendrickson to chief executive in light of Papa's departure.
Shares of Perrigo slumped 11.2 percent to $107.81 in opening trade, while Valeant rose 2.3 percent to $36.86.
Explore further: Valeant CEO takes medical leave